Back to discover
Disease

Thyrotoxicosis

Late-stage therapeutic developmentEmerging research
2
Publications
2
Clinical trials
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Approval: Emcitate (EMA)

Regulatory2025-02-12EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Tiratricolapproved

Approval — Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with mon… (2025)

Clinical trials

2 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
2
All trials
0
Active
1
Late-stage
2
Completed
Late-stage studies

A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People

Phase 3 · Completed · Newcastle-upon-Tyne Hospitals NHS Trust

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2025emaApprovalTiratricol· Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20162020
Most influential

Thyrotoxicosis in patients with COVID-19: the THYRCOV study.

European journal of endocrinology · 2020 · 232 cites
Recent publications

Thyrotoxicosis in patients with COVID-19: the THYRCOV study.

European journal of endocrinology · 2020 · 232 cites
Major themes2
  • Evidence-Based Medicine1
  • Precision Medicine1
Leading journals2
  • European journal of endocrinology1
  • Thyroid : official journal of the American Thyroid Association1
Leading researchers8
  • Burch HB1
  • Cellini M1
  • Cooper DS1
  • Greenlee MC1
  • Lania A1
  • Laurberg P1
  • Lavezzi E1
  • Maia AL1
Affiliations (unnormalised)6
  • 1 Massachusetts General Hospital1
  • 11 Institute of Nuclear Medicine1
  • 5 Departments of Clinical Medicine and Endocrinology1
  • Diabetes and Clinical Nutrition1
  • Duke University School of Medicine1
  • Hospital de Clinicas de Porto Alegre1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.